Dansyl-PQRamide, a putative antagonist of NPFF receptors, reduces anxiety-like behavior of ethanol withdrawal in a plus-maze test in rats

Peptides

Volumn 30, Issue 6, 2009, Pages 1165-1172

  Kotlinska, Jolanta ^a   Pachuta, Agnieszka ^a   Bochenski, Marcin ^a   Silberring, Jerzy ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Anxiety; Dansyl PQRamide; Elevated plus maze; Ethanol withdrawal; Naloxone; NPFF

Indexed keywords

ALCOHOL; DANSYL CHLORIDE; DANSYL PROLYLGLUTAMYLARGINYLAMIDE; NALOXONE; NEUROPEPTIDE FF; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ALCOHOL WITHDRAWAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANXIETY; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; MAZE LEARNING; NALOXONE; NEUROPEPTIDES; RATS; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALIA; RATTUS;

EID: 67349199967     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.02.002     Document Type: Article

References (85)

1. Aguirre J.C., Del Arbol J.L., Raya J., Ruiz-Requena M.E., and Rico Irles J. Plasma beta-endorphin levels in chronic alcoholics. Alcohol 7 (1990) 409-412
2. Akil H., Watson S.J., Young E., Lewis M.E., Khachaturian H., and Walker J.M. Endogenous opioids: biology and function. Annu Rev Neurosci 7 (1984) 223-255
3. Altshuler H.L., Phillips P.E., and Feinhandler D.A. Alteration of ethanol self-administration by naltrexone. Life Sci 26 (1980) 679-688
4. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., and Britton K.T. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology 103 (1991) 227-232
5. Banks W.A., Wolf K.M., and Niehoff M.L. Effects of chronic ethanol on brain and serum level of methionine enkephalin. Peptides 24 (2003) 1935-1940
6. Bertoglio L.J., and Carobrez A.P. Anxiolytic effects of ethanol and phenobarbital are abolished in test-experienced rats submitted to the elevated plus maze. Pharmacol Biochem Behav 73 (2002) 963-969
7. Bhattacharya S.K., Chakrabarti A., Sandler M., and Glover V. Rat brain monoamine oxidase A and B inhibitory (tribulin) activity during drug withdrawal anxiety. Neurosci Lett 199 (1995) 103-106
8. Borg S., Kvande H., Rydberg U., Terenius L., and Wahlström A. Endorphin levels in human cerebrospinal fluid during alcohol intoxication and withdrawal. Psychopharmacology 78 (1982) 101-103
9. Britton D.R., and Britton K.T. A sensitive open field measure of anxiolytic drug activity. Pharmacol Biochem Behav 15 (1981) 577-582
10. Cole J.C., Littleton J.M., and Little H.J. Acamprosate, but not naltrexone, inhibits conditioned abstinence behavior associated with repeated ethanol administration and exposure to a plus-maze. Psychopharmacology 147 (2000) 403-411
11. Costall B., Jones B.J., Kelly M.E., Naylor R.J., and Tomkins D.M. Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol Biochem Behav 32 (1989) 777-785
12. Cox B.M., Chavkin C., Christie M.J., Civelli O., Evans C., and Hamon M.D. The IUPHAR compendium of receptor characterization and classification (2000), IUPHAR Media Ltd., London p. 321-33
13. Doremus T.L., Brunell S.C., Varlinskaya E.I., and Spear L.P. Anxiogenic effects during withdrawal from acute ethanol in adolescent and adult rats. Pharmacol Biochem Behav 75 (2003) 411-418
14. Esel E., Sofuoglu S., Aslan S.S., Kula M., Yabanoglu I., and Turan M.T. Plasma levels of beta-endorphin, adrenocorticotropic hormone and cortisol during early and late alcohol withdrawal. Alcohol Alcohol 36 (2001) 572-576
15. Fang Q., Guo J., Peng Y.L., Chang M., He F., Chen Q., et al. In vitro and in vivo studies of dansylated compounds, the putative agonists and antagonists on neuropeptide FF receptors. Peptides 27 (2006) 1297-1304
16. Fang Q., He F., Wang Y.Q., Guo J., Zhang B.Z., Chen Q., et al. Pharmacological effects of the dansylated neuropeptide FF analogues on body temperature and morphine analgesia. Neuropeptides 41 (2007) 339-347
17. Fanselow M.S., and Cramer C.P. The ontogeny of opiate tolerance and withdrawal in infant rats. Pharmacol Biochem Behav 31 (1988) 431-438
18. Gatch M.B., Wallis C.J., and Lal H. Effects of NMDA antagonists on ethanol-withdrawal induced "anxiety" in the elevated plus maze. Alcohol 19 (1999) 207-211
19. Ghozland S., Chu K., Kieffer B.L., and Roberts A.J. Lack of stimulant and anxiolytic-like effects of ethanol and accelerated development of ethanol dependence in mu-opioid receptor knockout mice. Neuropharmacology 49 (2005) 493-501
20. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem 4 (2004) 39-50
21. Gouardères C., Tafani J.A., and Zajac J.M. Affinity of neuropeptide FF analogs to opioid receptors in the rat spinal cord. Peptides 19 (1998) 727-730
22. Hall F.S., Huang S., Fong G.W., Pert A., and Linnoila M. Effects of isolation-rearing on locomotion, anxiety and responses to ethanol in Fawn Hooded and Wistar rats. Psychopharmacology 139 (1998) 203-209
23. Hall F.S., Sora I., and Uhl G.R. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology 154 (2001) 43-49
24. Hayward M.D., Hansen S.T., Pintar J.E., and Low M.J. Operant self-administration of ethanol in C57BL/6 mice lacking beta-endorphin and enkephalin. Pharmacol Biochem Behav 79 (2004) 171-181
25. Hebb A.L., and Zacharko R.M. Central D-Ala2-Met5-enkephalinamide mu/delta-opioid receptor activation reverses the anxiogenic-like properties of cholecystokinin on locomotor and rearing activity in CD-1 mice. Brain Res 970 (2003) 9-19
26. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology 129 (1997) 99-111
27. Ho A.K., and Rossi N. Suppression of ethanol consumption by MET-enkephalin in rats. J Pharm Pharmacol 34 (1982) 118-119
28. Huang E.Y., Li J.Y., Wong C.H., Tan P.P., and Chen J.C. Dansyl-PQRamide, a possible neuropeptide FF receptor antagonist, induces conditioned place preference. Peptides 23 (2002) 489-496
29. Hutchison W.D., Gianoulakis C., and Kalant H. Effects of ethanol withdrawal on beta-endorphin levels in rat brain and pituitary. Pharmacol Biochem Behav 30 (1988) 933-939
30. Inder W.J., Livesey J.H., and Donald R.A. Peripheral plasma levels of beta-endorphin in alcoholics and highly trained athletes and the relationship to a measure of central opioid tone. Horm Metab Res 30 (1998) 523-525
31. Kiefer F., Horntrich M., Jahn H., and Wiedemann K. Is withdrawal-induced anxiety in alcoholism based on beta-endorphin deficiency?. Psychopharmacology 162 (2002) 433-437
32. Koob G.F., and Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24 (2001) 97-129
33. Koob G.F., Roberts A.J., Kieffer B.L., Heyser C.J., Katner S.N., Ciccocioppo R., et al. Animal models of motivation for drinking in rodents with a focus on opioid receptor neuropharmacology. Recent Dev Alcohol 16 (2003) 263-281
34. Kotlinska J., and Bochenski M. The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. Eur J Pharmacol 598 (2008) 57-63
35. Kotlinska J., and Langwinski R. Audiogenic seizures during ethanol withdrawal can be blocked by a delta opioid agonist. Drug Alcohol Depend 18 (1986) 361-367
36. Kotlinska J., and Langwinski R. Does the blockade of opioid receptors influence the development of ethanol dependence?. Alcohol Alcohol 22 (1987) 117-119
37. Kotlinska J., Pachuta A., Dylag T., and Silberring J. Neuropeptide FF (NPFF) reduces the expression of morphine- but not of ethanol-induced conditioned place preference in rats. Peptides 28 (2007) 2235-2242
38. Kotlinska J., Pachuta A., Dylag T., and Silberring J. The role of neuropeptide FF (NPFF) in the expression of sensitization to hyperlocomotor effect of morphine and ethanol. Neuropeptides 41 (2007) 51-58
39. Kotlinska J., Pachuta A., and Silberring J. Neuropeptide FF (NPFF) reduces the expression of cocaine-induced conditioned place preference and cocaine-induced sensitization in animals. Peptides 29 (2008) 933-939
40. Krishnan-Sarin S., Portoghese P.S., Li T.K., and Froehlich J.C. The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol Biochem Behav 52 (1995) 153-159
41. Kudryavtseva N.N., Gerrits M.A., Avgustinovich D.F., Tenditnik M.V., and Van Ree J.M. Modulation of anxiety-related behaviors by mu- and kappa-opioid receptor agonists depends on the social status of mice. Peptides 25 (2004) 1355-1363
42. LaBuda C.J., and Hale R.L. Anxiety in mice following acute aspartame and ethanol exposure. Alcohol 20 (2000) 69-74
43. Lake J.R., Hammond M.V., Shaddox R.C., Hunsicker L.M., Yang H.Y., and Malin D.H. IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci Lett 132 (1991) 29-32
44. 2 like mammalian octapeptide in opiate dependence and withdrawal. NIDA Res Monogr 105 (1990) 271-277
45. Malin D.H., Lake J.R., Smith D.A., Jones J.A., Morel J., Claunch A.E., et al. Subcutaneous injection of an analog of neuropeptide FF prevents naloxone-precipitated morphine abstinence syndrome. Drug Alcohol Depend 40 (1995) 37-42
46. Marchand S., Betourne A., Marty V., Daumas S., Halley H., Lassalle J.M., et al. A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice. Peptides 27 (2006) 964-972
47. Mauborgne A., Bourgoin S., Poliénor H., Roumy M., Simonnet G., Zajac J.M., et al. The neuropeptide FF analogue, 1DMe, acts as a functional opioid autoreceptor antagonist in the rat spinal cord. Eur J Pharmacol 430 (2001) 273-276
48. Motta V., and Brandão M.L. Aversive and antiaversive effects of morphine in the dorsal periaqueductal gray of rats submitted to the elevated plus-maze test. Pharmacol Biochem Behav 44 (1993) 119-125
49. O'Brien C.P., Volpicelli L.A., and Volpicelli J.R. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 13 (1996) 35-39
50. O'Malley S.S., Krishnan-Sarin S., Farren C., Sinha R., and Kreek M.J. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl) 160 (2002) 19-29
51. Pandey S.C., Zhang D., Mittal N., and Nayyar D. Potential role of the gene transcription factor cyclic AMP-responsive element binding protein in ethanol withdrawal-related anxiety. J Pharmacol Exp Ther 288 (1999) 866-878
52. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 5th ed. (2005), Elsevier Academic Press, San Diego p. 1-367
53. Payza K., Akar C.A., and Yang H.Y. Neuropeptide FF receptors: structure-activity relationship and effect of morphine. J Pharmacol Exp Ther 267 (1993) 88-94
54. Pellow S., and File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated olus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24 (1986) 525-529
55. Prokai L., Prokai-Tatrai K., Zharikova A., Li X., and Rocca J.R. Combinatorial lead optimization of a neuropeptide FF antagonist. J Med Chem 44 (2001) 1623-1626
56. Prokai L., Zharikova A.D., Juhasz A., and Prokai-Tatrai K. Cardiovascular effects of neuropeptide FF antagonists. Peptides 27 5 (2006) 1015-1019
57. Prunell M., Boada J., Feria M., and Benitez M.A. Antagonism of the stimulant and depressant effects of ethanol in rats by naloxone. Psychopharmacology 92 (1987) 215-218
58. Quelven I., Roussin A., Burlet-Schiltz O., Gouardères C., Tafani J.A., Mazarguil H., et al. Dissociation of pharmacological pro- and anti-opioid effects by neuropeptide FF analogs. Eur J Pharmacol 449 (2002) 91-98
59. Rasmussen D.D., Bryant C.A., Boldt B.M., Colasurdo E.A., Levin N., and Wilkinson C.W. Acute alcohol effects on opiomelanocortinergic regulation. Alcohol Clin Exp Res 22 (1998) 789-801
60. Rasmussen D.D., Mitton D.R., Green J., and Puchalski S. Chronic daily ethanol and withdrawal. 2. Behavioral changes during prolonged abstinence. Alcohol Clin Exp Res 25 (2001) 999-1005
61. Rivier C., and Vale W. Interaction between ethanol and stress on ACTH and beta-endorphin secretion. Alcohol Clin Exp Res 12 (1988) 206-210
62. Roberts A.J., Gold L.H., Polis I., McDonald J.S., Filliol D., Kieffer B.L., et al. Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol Clin Exp Res 25 (2001) 1249-1256
63. Roberts A.J., McDonald J.S., Heyser C.J., Kieffer B.L., Matthes H.W., Koob G.F., et al. mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 293 (2000) 1002-1008
64. Roussin A., Serre F., Gouardères C., Mazarguil H., Roumy M., Mollereau C., et al. Anti-analgesia of a selective NPFF2 agonist depends on opioid activity. Biochem Biophys Res Commun 336 (2005) 197-203
65. Sandi C., Borrell J., and Guaza C. Enkephalins interfere with early phases of voluntary ethanol drinking. Peptides 11 (1990) 697-702
66. Schulteis G., and Liu J. Brain reward deficits accompany withdrawal (hangover) from acute ethanol in rats. Alcohol 39 (2006) 21-28
67. Schulteis G., Markou A., Cole M., and Koob G.F. Decreased brain reward produced by ethanol withdrawal. Proc Natl Acad Sci USA 92 (1995) 5880-5884
68. Schulteis G., Yackey M., Risbrough V., and Koob G.F. Anxiogenic-like effects of spontaneous and naloxone-precipitated opiate withdrawal in the elevated plus-maze. Pharmacol Biochem Behav 60 (1998) 727-731
69. Schulz R., Wüster M., Duka T., and Herz A. Acute and chronic ethanol treatment changes endorphin levels in brain and pituitary. Psychopharmacology 68 (1980) 221-227
70. Schwartz M., Schwartz D., Bauer M.L., Borison R.L., and Diamond B.I. Alcohol dependence and withdrawal and brain endorphins. Neurology 31 (1981) 62
71. Sher L. The role of the endogenous opioid system in the pathogenesis of anxiety disorders. Med Hypotheses 50 (1998) 473-474
72. Stopponi S., Economidou D., Braconi S., Bartocci P., Ciccocioppo R., and Massi M. Alcohol withdrawal symptoms are reduced by central administration of nociceptin/orphanin FQ. European opioid conference, EOC-ENC 2008 joint meeting. Ferrara (2008) 69 [abstract]
73. Stromberg M.F., Casale M., Volpicelli L., Volpicelli J.R., and O'Brien C.P. A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat. Alcohol 15 (1998) 281-289
74. Swift R.M. Opioid antagonists and alcoholism treatment. CNS Spectr 5 (2000) 49-57
75. Tan P.P., Chen J.C., Li J.Y., Liang K.W., Wong C.H., and Huang E.Y. Modulation of naloxone-precipitated morphine withdrawal syndromes in rats by neuropeptide FF analogs. Peptides 20 (1999) 1211-1217
76. Urayama A., King K., Gaskin F.S., Farr S.A., and Banks W.A. Effects of chronic ethanol administration on brain interstitial fluid levels of methionine-enkephalin as measured by microdialysis in vivo. Peptides 27 (2006) 2201-2206
77. Van der Goltz C.H., Mutschler J., Jahn H., Wiedemann K., and Kiefer F. Anxiolytic activity of atrial natriuretic peptide and β-endorphin during acute ethanol withdrawal in mice. Eur Psych 23 (2008) S312
78. Vergura R., Balboni G., Spagnolo B., Gavioli E., Lambert D.G., McDonald J., et al. Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides 29 (2008) 93-103
79. Vescovi P.P., Coiro V., Volpi R., Giannini A., and Passeri M. Plasma beta-endorphin, but not met-enkephalin levels are abnormal in chronic alcoholics. Alcohol Alcohol 27 (1992) 471-475
80. Volpicelli J.R., Alterman A.I., Hayashida M., and O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49 (1992) 876-880
81. Volpicelli J.R., Volpicelli L.A., and O'Brien C.P. Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Alcohol Alcohol 30 (1995) 789-798
82. Weiss F., Ciccocioppo R., Parsons L.H., Katner S., Liu X., Zorrilla E.P., et al. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci 937 (2001) 1-26
83. Zajac J.M. Neuropeptide FF: new molecular insights. Trends Pharmacol Sci 22 (2001) 63
84. Zarrindast M.R., Babapoor-Farrokhran S., Babapoor-Farrokhran S., and Rezayof A. Involvement of opioidergic system of the ventral hippocampus, the nucleus accumbens or the central amygdala in anxiety-related behavior. Life Sci 82 (2008) 1175-1181
85. Zhang Z., and Schulteis G. Withdrawal from acute morphine dependence is accompanied by increased anxiety-like behavior in the elevated plus maze. Pharmacol Biochem Behav 89 (2008) 392-403